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Latar belakang  
Uji kaji rawak secara selari di satu pusat tunggal ini dijalankan ke atas dua pulud dua 
pesakit Kencing Manis Jenis Satu (T1DM) dengan purata umur 14 tahun. Peserta 
dibahagikan kepada dua kumpulan, kawalan dan intervensi.  
 
Objektif  
Objektif ujikaji ini adalah membandingkan kawalan glicemik dan kekerapan episod 
hipoglicemia antara Sistem Pemantauan Gula Berterusan (CGMS) dan Pemantauan Gula 
Sendiri Berkala (SMBG) dalam kalangan kanak-kanak yang menghidap Kencing Manis 
Jenis 1 (T1DM).  
 
Intervensi 
Setiap peserta memakai alat CGMS pada permulaan ujikaji. Dos insulin kumpulan 
intervensi (n=11) ditentukan berdasarkan maklumat daripada alat CGMS manakala 
kumpulan kawalan (n=11) berdasarkan maklumat daripada data SMBG. Bacaan gula 
(BSL) purata dalam sebulan dan purata bilangan episod hipoglicemia dalam seminggu 
(HE/wk) setiap bulan diukur pada permulaan, bulan pertama, kedua dan ketiga. HbA1c 






Ciri-ciri asal peserta dalam setiap kumpulan adalah sepadan. Segala data dianalisis 
menggunakan kaedaah Analisis Variasi Berulang (ANOVA). Beza purata HbA1c dalam 
kumpulan adalah tidak ketara, p=0.322. Terdapat perbezaan ketara dalam purata bulanan 




Dalam mengoptimakan kawalan glicemik, CGMS dan SMBG adalah setara, namun 










CONTINUOUS GLUCOSE MONITORING SYSTEM VERSUS SELF-
MONITORING BLOOD GLUCOSE IN TYPE 1 DIABETES CHILDREN 




A single centre, randomized, parallel-group controlled trial was conducted involving 
twenty-two type one Diabetes Mellitus (T1DM) patients with the mean age of 13.8 years 
assigned to either intervention or control group.  
  
Objectives 
The primary and secondary objectives were to compare the glycaemic control and 
frequency of hypoglycaemia between Continuous Glucose Monitoring System (CGMS) 







All respondents wore the CGMS device at the beginning of the study. Intervention group 
(n=11) had their insulin adjusted based on the CGMS data, while the control group (n=11) 
were based on SMBG. Monthly average blood sugar level (BSL) and monthly mean 
hypoglycemic events per week (HE/wk) were measured at baseline, first month, the 




The baseline characteristics were similar. The data were analysed using repeated measure 
analysis of variance (ANOVA). The mean difference of HbA1c within the group was not 
statistically significant with p=0.322. There were significant differences in the monthly 
mean HE/wk within and between groups, p=0.004, and p=0.037.  
  
Conclusion 
In conclusion, CGMS is equivalent to SMBG in optimising glycaemic control but is more 


















The incidence of Type 1 Diabetes Mellitus (T1DM) is increasing by 3% annually 
worldwide1,2. T1DM is the most common form of Diabetes Mellitus (DM) and accounts 
for 74.4% of all diabetic children and adolescents in Malaysia. T1DM is associated with 
various neurological and cardiovascular complications1,3. It has a seven times higher risk 
of death from coronary heart disease compared to the normal population and two times 
more than in Type 2 Diabetes Mellitus4. A good glycaemic control reduced the risk of 
neuropathy and a more than 50% reduction in the early stages of microvascular 
complications such as retinopathy and nephropathy in patients with T1DM5. Few factors 
could affect glycaemic control among children and adolescents with T1DM. These 
include age6, BMI, high daily basal insulin dose1,7, duration of diabetes8-10, compliance 
to blood glucose monitoring and insulin regimen11-13, types of insulin, and quality of 
life14,15. 
  
In Malaysia, more than 50% of T1DM patients age less than twenty years old have poor 
glycaemic control with HbA1c of more than 10.0%1. Managing adolescents with T1DM 
is a great challenge to clinicians and family members. Adolescents, in general, have 
poorer glycaemic control and more severe hypoglycaemic events compared to children 
and adults16. This poor control is because they have poorer adherence to dietary 
restriction, treatment plan, and glucose monitoring associated with various psychosocial 
factors such as fear of social rejection from peers, risk-taking behaviour, affective 
disorders such as anxiety and depression, and burnout1,2,16. This problem had drawn a lot 
of attention from various stakeholders to come out with better, more convenient, and 
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affordable forms of blood sugar monitoring and methods to administer insulin to 
overcome some of the known limitations in the management of T1DM. 
  
Good metabolic control can be achieved with intensive therapy and more frequent 
monitoring of blood glucose4,9,14. Self-monitoring blood glucose (SMBG) has been the 
conventional means of blood glucose monitoring at home. However, SMBG only 
provides intermittent readings of glucose level without giving a whole 24-hour-picture of 
glucose variability. Alternatively, the Continuous Glucose Monitoring System (CGMS) 
was introduced in the early year 2000. CGMS measures subcutaneous interstitial fluid 
glucose every few minutes for a few days17. It offers the potential to optimize glycaemic 
control as well as to detect subclinical hypoglycaemic events. CGMS device can be 
integrated with an insulin pump to analyse and fine-tune the dose of insulin in either real-
time or retrospective more accurately18. 
  
In 2001, Chase et al in a randomized clinical trial involving small number of children 
with type 1 DM (n=11), all on intensive insulin therapy with HbA1c value of more than 
8.0% concluded that CGMS able to significantly reduced HbA1c without increasing 
hypoglycaemic events with the mean ± SD reduction in HbA1c of 0.36% ± 0.07% 
(p<0.01)16 In another study involving 28 Italian type 1 DM children with poor glycemic 
control, Silvana et al found that after 3 month and 6 month of using CGMS, HbA1c level 
reduced significantly compared to baseline HbA1c with p-value of 0.05 and 0.032 
respectively. The HbA1c level reduced significantly even among patient with poor 
compliant17. Similar finding was reported in a cross-over randomized controlled trial of 
27 diabetic patient aged 5-19 years, patients were randomised to two groups, namely an 
open and blind arm. In the open arm group, the continuous data (CGMS) was used to 
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guide the insulin adjustment, whilst in the blind arm, CGMS data were kept to 
investigator. After 3 months, the study arms were crossed over. HbA1c decreased 
significantly in the open arm from 7.70% to 7.31% (p = 0.013)18. 
In a randomized, controlled, multicentre study of 120 children and adults comparing 
continuous glucose monitoring (n = 62) to conventional home monitoring blood glucose 
level (n = 58), HbA1c level at 26 weeks post intervention, was lower in the continuous 
group than in the control group with a difference of -0.27%; 95% CI -0,47 to-0.07; p = 
0.008. Battelino et al in the same study also found that total duration per day of 
hypoglycemia, glucose level less than 63 mg/dL, was significantly shorter in the 
continuous glucose monitoring group (ratio of means 0.49 [95% CI 0.26–0.76], P = 0.03) 
Time spent in hypoglycemia below 70 mg/dL and below 55 mg/dL was significantly 
shorter in the continuous glucose monitoring group (P = 0.01 and P = 0.05 respectively)19. 
However, some studies unable to demonstrate the effectiveness of CGMS in improving 
glycemic control. For example, Yates et al concluded from a randomized control trial 
conducted among well control type 1 DM Australian children less than 18 years (HbA1c 
<10%), CGMS has no added value in improving glycemic control compared to 
intermittent finger-prick SMBG together with frequent outpatient reviews. [0.4% (95% 
CI 0.7 to 0.1)] vs [0.4% (95% CI 0.8 to 0.2)]20. Besides that, Yates et al found that each 
1% reduction in HbA1c among CGMS group was associated with 7% increase in period 
of hypoglycemia (R² 0.22, P  0.06) and an 18% increase in the percentage of nocturnal 
hypoglycaemia (R²  0.2, P  0.08)20. In the latest Cochrane meta-analysis in 2012, five 
randomized control trials of mixed design – parallel and crossover design, that involved 
T1DM children randomized into either retrospective CGMS or SMBG were analysed 21. 
Respondents in the intervention group wore CGMS device for three consecutive days 
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multiple times throughout the study period. HbA1c were taken at baseline and post 
intervention 8,14,18,22. There was no significant difference in the changes of mean HbA1c 
between the CGMS and SMBG users in all of the studies. 
This RoSEC (Research on Safety and Efficacy of Continuous Glucose Monitoring 
System) trial aims to determine whether the use of data from retrospective CGMS to fine-
tune insulin dosage would result in better HbA1c and average BSL per month without 
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Type 1 Diabetes is the most common type of diabetes among children and 
adolescents and the incidence is increasing by 3% per year worldwide2,23. Of the 
estimated 500,000 cases of type 1 diabetic children worldwide, 29% are from the South-
East Asian region and 26% from the Western Pacific region24. In Malaysia, it has been 
estimated that Type 1 Diabetes accounts for 74.4% of children and adolescents1.  
 
T1DM is associated with various complications including retinopathy, 
nephropathy, neuropathy and cardiovascular morbidity. In fact, T1DM is 7 times more 
risk for developing coronary heart disease compared to normal population and 2 times 
more than in T2DM3. In Malaysia, commonly reported complication was 
microalbuminuria in 8.5%, nephropathy (3.6%), retinopathy in 3.2% and neuropathy in 
1.0% of patient1. Risk factors for microangiopathic complications include poor glycemic 
control, duration of diabetes, family history of complications, onset of puberty, smoking, 
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hyperlipidemia and hypertension2. Diabetes Control and Complications Trial (DCCT) has 
demonstrated that a good glycemic control resulted in reduction of neuropathy and more 
than 50% reduction in the early stages of microvascular complications such as retinopathy 
and nephropathy in T1DM4. DCCT also concludes that with every 10% reduction of 
hba1c, 44% reduction of risk of diabetic complication will be achieved. 
 
Adolescent in general has poorer glycemic control and more severe hypoglycemic 
episodes compared to children and adult1,2. Unfortunately, in Malaysia, more than 50% 
of T1DM patients < 20 years of age had poor metabolic control with HbA1c > 10.0%1. 
Self-monitoring blood glucose (SMBG) has been a known tool to provide an immediate 
documentation of capillary blood glucose level via a glucometer. However, SMBG only 
delivered intermittent readings of glucose level without giving a whole 24-hour-picture 
of glucose variability. Alternatively, glucose level can be monitored continuously be 
reviewed retrospectively or real-time with continuous glucose monitoring system. 
Frequent monitoring of blood glucose allows average glucose level that correlates well 
with HbA1c level to be monitored and more intensive therapy given safely15.  
 
Hypoglycemia is one of the most serious complication of type 1 DM. 
Hypoglycemia is defined as glucose level of less than 3.6 mmol/L (65 mg/dL). However, 
a glucose value of <3.9 mmol/L (70 mg/dL) is the cut-off value for intervention25.    
Frequent and severe hypoglycemia can lead to permanent neurological damage and can 
reduce cognitive function in children26. Even though tight glycemic control can prevent 
microvascular complications, it can lead to increased risk of symptomatic 
hypoglycemia14. Besides that, frequent hypoglycemic episodes can reduce the counter-
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regulatory endocrine response and clinical neuroglycopenic symptoms and thus reduce 
awareness of hypoglycemia14.  
 
Due to this, a continuous glucose monitoring system (CGMS) was introduced 
more than 10 years ago which use minimally invasive device to measure continuous 
subcutaneous interstitial fluid glucose every 1 - 5 minutes in 24 hours15, CGMS offers the 
potential to optimize glycaemic control as well as detects subclinical hypoglycemic 
episodes as it provides a continuous data on variability of blood glucose levels throughout 
the day which will guide the adjustment of insulin more accurately14. 
 
1.2 Justification to Conduct the Study 
This RoSEC (Research on Safety and Efficacy of Continuous Glucose Monitoring 
System) trial aims to determine whether with the use of data from CGMS to fine tune 
insulin dosage would result in better glycaemic control without increasing the frequency 
of hypoglycemia. The recent systematic review, looking at the efficacy and safety of the 
continuous glucose monitoring system concluded that CGMS can improve glycemic 
control among type 1 DM adult and children, however half of the study were of poor 
quality (jaded score <3) with small sample size and short duration of study27. Besides 
that, to date, there is no similar study done in Malaysia or Southeast Asia region to look 
at the effectiveness of CGMS in improving glycemic control. Furthermore, the sample 
population of the previous clinical trials have much lower mean HbA1c level compared 
to children and adolescent with type 1 DM in HUSM based on a preliminary retrospective 
study on this cohort that found that mean HbA1c among this cohort is much higher (mean 
11.0, s.d 2.31)28,29. Therefore, with this RCT, we are hoping to improve not only the 
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glycaemic control but also the rate of hypoglycaemia among our patients by using the 
data from CGMS to fine tuning the diabetic management. 
 
1.3 Literature Review 
In 2001, Chase et al in a randomized clinical trial involving small number of 
children with type 1 DM (n=11), all on intensive insulin therapy with HbA1c value of 
more than 8.0% concluded that CGMS able to significantly reduced HbA1c without 
increasing hypoglycaemic events with the mean ± SD reduction in HbA1c of 0.36% ± 
0.07% (p<0.01)16 In another study involving 28 Italian type 1 DM children with poor 
glycemic control, Silvana et al found that after 3 month and 6 month of using CGMS, 
HbA1c level reduced significantly compared to baseline HbA1c with p-value of 0.05 and 
0.032 respectively. The HbA1c level reduced significantly even among patient with poor 
compliant17. Similar finding was reported in a cross-over randomized controlled trial of 
27 diabetic patient aged 5-19 years, patients were randomised to two groups, namely an 
open and blind arm. In the open arm group, the continuous data (CGMS) was used to 
guide the insulin adjustment, whilst in the blind arm, CGMS data were kept to 
investigator. After 3 months, the study arms were crossed over. HbA1c decreased 
significantly in the open arm from 7.70% to 7.31% (p = 0.013)18. 
In a randomized, controlled, multicentre study of 120 children and adults 
comparing continuous glucose monitoring (n = 62) to conventional home monitoring 
blood glucose level (n = 58), HbA1c level at 26 weeks post intervention, was lower in the 
continuous group than in the control group with a difference of -0.27%; 95% CI -0,47 to-
0.07; p = 0.008. Battelino et al in the same study also found that total duration per day of 
hypoglycemia, glucose level less than 63 mg/dL, was significantly shorter in the 
continuous glucose monitoring group (ratio of means 0.49 [95% CI 0.26–0.76], P = 0.03) 
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Time spent in hypoglycemia below 70 mg/dL and below 55 mg/dL was significantly 
shorter in the continuous glucose monitoring group (P = 0.01 and P = 0.05 respectively)19. 
However, some studies unable to demonstrate the effectiveness of CGMS in 
improving glycemic control. For example, Yates et al concluded from a randomized 
control trial conducted among well control type 1 DM Australian children less than 18 
years (HbA1c <10%), CGMS has no added value in improving glycemic control 
compared to intermittent finger-prick SMBG together with frequent outpatient reviews. 
[0.4% (95% CI 0.7 to 0.1)] vs [0.4% (95% CI 0.8 to 0.2)]20. Besides that, Yates et al found 
that each 1% reduction in HbA1c among CGMS group was associated with 7% increase 
in period of hypoglycemia (R² 0.22, P  0.06) and an 18% increase in the percentage of 
nocturnal hypoglycaemia (R²  0.2, P  0.08)20. In the latest Cochrane meta-analysis in 2012, 
five randomized control trials of mixed design – parallel and crossover design, that 
involved T1DM children randomized into either retrospective CGMS or SMBG were 
analysed 21. Respondents in the intervention group wore CGMS device for three 
consecutive days multiple times throughout the study period. HbA1c were taken at 
baseline and post intervention 8,14,18,22. There was no significant difference in the changes 
of mean HbA1c between the CGMS and SMBG users in all of the studies. 
 
1.4. Research Hypothesis 
There is a significant difference in HbA1c and number of hypoglycemic episodes per 
week when the data of CGMS is used to fine-tune the diabetic management as compared 





1.5. General Objective 
To determine the efficacy and safety of continuous glucose monitoring system in 
management of Type 1 Diabetes Mellitus Children 
 
 
1.6. Specific Objective 
1. To compare the glycaemic control between intervention and control group in 
paediatric T1DM  
2. To compare numbers of hypoglycemic episodes per week detected by CGMS 
compare to detected via SMBG 






2.1. Trial Design 
A single center, randomized, double-blind, and parallel-group controlled trial with equal 
randomization (allocation ratio 1:1) conducted at Hospital Universiti Sains Malaysia. 
Subjects are randomly assigned into one of two arms, the control and intervention arm. 
The intervention arm is the intervention group while the control arm is the control group. 
Figure 1 depicts the conceptual framework of this study. 
 
2.2. Eligibility Criteria for Participants 
Participants of the study are any patients diagnosed with T1DM and were followed up at 
HUSM Kubang Kerian, Kelantan. 
 
2.2.1 Inclusion criteria for the study; 
a)  Age more than 7 years old    
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b)  Diagnosed with T1DM for at least 12 months (to exclude Partial 
Remission Period)  
c)  On intensive Regimen which are three or more daily insulin injections  
d)  Baseline HbA1c > 7.0% or frequent hypoglycemic episodes of >10% of 
monitoring per week. 
 
2.2.2 Exclusion criteria for the study; 
a) Other type of Diabetes namely Type 2 Diabetes, Maturity-onset diabetes 
in youth 
(MODY) and Neonatal Diabetes. 
b)  Patient on conventional insulin regimen which are one to two times a day 
injection of self-mixed or premixed insulin  
c)   Syndromic or dysmorphic patients 
 
2.2.3 Withdrawal criteria 
As the completion of the observation needs 3 monthly interval of HbA1c 
monitoring, any patients who do not turn up for blood taking after 3 months post 
CGMS and poor SMBG records will be withdrawn from the study. 
 
2.3. Study Area 
The study was conducted in Paediatric Diabetic Clinic Hospital USM, Kubang Kerian, 
Kelantan. The hospital is a teaching hospital for University Sains Malaysia and where the 
Health Campus located. Kubang Kerian is one of the major towns of Kelantan, a state in 
Malaysia where majority of its population are Malays from different socio-economic 
background.  The paediatric endocrine clinic is the referral centre for paediatric endocrine 
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services in East Coast Malaysia. Therefore, patients that were followed-up here came 
from wide geographical area with the distance of travelling reaching 190km.  
 
2.4. Intervention 
In the intervention arm, patients will wear CGMS for 1 week at the beginning of the study 
on top of their usual 4 times per day pre-prandial self-glucose monitoring. After 1 week, 
the device will be removed and the data will be downloaded and analyzed. 
Endocrinologist will adjust the dose of insulin to be injected by patient for the next 3 
month based on the data. Throughout the whole 12 weeks period, patients will continue 
their usual pre-prandial capillary blood glucose monitoring 4 times per day. HbA1c will 
be measured at baseline and at end of week12 while frequency of hypoglycemic episodes 
based on patient SMBG at week 1 and at week 12 will be obtained. 
 
In the control arm, patients will also wear CGMS for 1 week at the beginning of the study 
on top of their usual 4 times per day pre-prandial self-glucose monitoring. After 1 week, 
the device will be removed and the data will be downloaded but kept stored without being 
analyzed. Endocrinologist will adjust the dose of insulin to be injected by patient for the 
next 3 month solely based on the recording of their pre-prandial capillary blood glucose 
monitoring. Throughout the whole 12 weeks period, patients will continue their usual pre-
prandial capillary blood glucose monitoring 4 times per day. HbA1c will be measured at 
baseline and at end of week12. On top of that, mean SMBG per month at 1,2 and 3 month 
post insulin adjustment will be calculated based on patient daily SMBG. Average weekly 
hypoglycemic episode at month 1, 2 and 3 post insulin adjustment will also be calculated 






Phase 0 (Enrolment)  
Visit 0: Informed consent, baseline HbA1c measurement, clinical history 
review applicable inclusion and exclusion criteria, obtain consent 
Randomization into intervention and control arm 
 
Phase 1 (Baseline evaluation) 
Visit 1: Sometime after visit 0 patients will come for CGM device placement 
Patient will use CGM for 1 week to obtain baseline data and to evaluate compliance with using 
CGM.  
Patient in control arm will be wearing the CGM for 1 week but will be blinded.  
Visit 2: CGM will be removed after 1 week 
The data will be downloaded and analyzed for patient in intervention arm while downloaded 
and stored in control arm. 
Insulin dose for the next 12 weeks will be decided by endocrinologist based on CGMS data in 
intervention arm while based on SMBG data in the control arm  
 
Phase 2 (Follow-up) 
Visit 3: All patients will continue the insulin dose decided during visit 2 while continue pre-
prandial SMBG 4 times per day. 
Compliance to insulin and SMBG and general condition of patient including episodes of 
hypoglycemia will be reviewed. 
Patient will receive regular phone call to ensure compliance to insulin dose and SMBG and to 
ask general condition of patient.  
Visit 4:  Patient will be reviewed in clinic after 3 months. Mean glucose level and average 
number of hypoglycemia episode per week on month 1,2 and 3 post insulin adjustment will be 
calculated. 
HbA1c will be measured at the end of week 12 
Data collection period ended. 
Figure 2: RoSEC Study Design 
2.5. Outcomes 
The primary outcome of the study is HbA1c level. HbA1c will be measured 2 times, at 
the beginning of the study period (baseline) and at the end of week 12. The mean HbA1c 
value pre and post-intervention at 3 months within the group will be compared. This is to 
determine the effectiveness of both CGMS and SMBG. Comparison of mean HbA1c 
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between the arms post-intervention will determine the significance of CGMS compared 
to SMBG in improving glycemic control of patients. 
 
Secondary outcomes are the mean frequency of hypoglycemic episodes per week and 
mean glucose level per month at month 1, 2 and 3 post insulin adjustment. Hypoglycemia 
is defined as glucose level of less 3.9 mmol/L detected and recorded by patient using 
SMBG. These will be used to determine the efficacy and safety of CGMS. 
 
2.6. Sample Size 
Changes in glycemic control (HbA1c) within group pre and post intervention is the 
primary outcome of RoSEC. Sample size was estimated using sample size formula30:  
n = 2 + C (s/d)2 
where n is the sample size, s is the population standard deviation and d is the difference 
of mean to be detected. C is a constant based on α and 1- β,  
1- β / α 0.05 0.01 
0.8 7.85 11.68 
0.9 10.51 14.88 
 
In a previous study, within group mean difference of HbA1c has standard deviation 1.131 
If the mean difference to be detected based on expert views is 1. We will need to study 
20 subjects to be able to reject the null hypothesis that the mean within groups pre and 
post intervention are equal, with the power of study 0.80. The Type 1 error probability 
associated with the test of this null hypothesis is 0.05. Taking into accounts no drop rate, 
total sample size required is 22. 
 
2.7. Research Tools 
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Continuous glucose monitoring device used is Medtronic iPro2 Professional CGM device 
with enlite sensor. The device safety and efficacy has been established and was approved 
by FDA. Glucose value are not displayed to patient and has to be downloaded into the 
CGMs software and retrospectively evaluated during device removal. Intermittent 
capillary prick glucose monitoring was standardized using accu-chek performa 
glucometer with accu-chek performa test strips. Results appear in 5 seconds. It is 
convenient and easy to use with high accuracy. The device will be used by patient to 
monitor pre-prandial glucose level and to calibrate the CGMS device daily. HbA1c is 
measured using ion exchange high performance liquid chromatography technique at 
HUSM endocrine lab. The machine is calibrated every 2 weekly. The machine runs in 
batches every 2 to 3 days where the results will be available from the online lab results 
application accessible only to clinicians. CGMS will be downloaded using online 
software Medtronic CareLinkiPro Software that requires username and password to sign 
in. the data will be stored online and can be access through any computer with internet 





3.1. Sequence Generation 
No sampling was done in this study. All type 1 diabetes mellitus children and adolescent 
more than 7 years old that were diagnosed with T1DM attending follow up under HUSM 
that fulfilled the inclusion and exclusion criteria are included in the study. Stratified 
randomization method is used to ensure similar number of patient on insulin pump and 
on self-injection in both groups. The random allocation sequence will be generated using 
website https://www.randomizer.org/. Two allocation sequences will be generated by the 
website. Each sequence will either be the control or intervention group. Random 




3.2 Allocation Concealment Mechanism and Implementation 
The allocation procedure will be done by a dedicated research assistant not involved in 
the data collection and analysis. Interventionist (endocrinologist) and data collector will 
not involve in the allocation procedure. Patients will have to choose sealed opaque 
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envelope containing random numbers that is part of the allocation sequence during pre-
study clinic visit. The chosen envelope will be kept in a dedicated drawer. The research 
assistant will open the envelope, identify the number chosen and the group allocation on 
different setting and time in the absent of patient and endocrinologist. The allocation will 
be made known only to the clinicians involved in the study. Patients will not be informed 
the number and the group allocation. 
 
3.3 Blinding  
Some parties involved in this research will be kept blinded throughout the study period. 
Patients will be kept blinded on the arm they are in, the CGMS data and the HbA1c. 
Research Assistants who helps in downloading the CGMS data will be made blind on the 
identity of the patient and the arm they are in. Patient will be anonymous and only be 
identified by the allocation number. Clinic nurses will not be told the participation of 
subjects into the trial and the CGMS and SMBG data will be kept blind from them. Other 
clinicians besides the interventionist and data collectors will be blinded form the CGMS 
data and outcomes. The lab technician who runs the HbA1c test will be kept blind on 
patients’ participation into the study. All patients in both arms will be blinded and undergo 
the same procedure and investigation. Therefore, all patients will be given the same 
instruction and briefing at the beginning of the study. Patient will be identified with a 
research number throughout the study.  
 
3.4 Statistical Methods 
Data will be entered and analysed using SPSS version 24. The demographic and 
numerical data were presented by mean (SD) and median (IQR) according to data 
distribution. The categorical data were expressed as number and percentage. Repeated 
23 
 
measure ANCOVA will be used to determine the significance of the mean HbA1c 
difference between groups, within groups and between-within groups. From literatures, 
factors affecting glycemic control include age, BMI, daily basal insulin dose, duration of 
diabetes, type of insulin delivery, type of insulin. The number of hypoglycemia is 
presented in discrete numerical data and the mean difference between pre and post 
intervention in the intervention group will be analyzed using paired t-test if the outcome 
variable is normally distributed or using Wilcoxon Signed-Ranks test using median 
difference if the data is non-parametric. The mean difference between number of 
hypoglycemia per week detected by CGMS and SMBG will be compared using paired t-








4.1. Data Collection Method 
Data will be collected from online pathology laboratory results, from the CGMS analysis 
software and patient’s own blood glucose monitoring record and will be documented in 
a data collection form. Then, all data will be entered into SPSS software anonymously. 
Only research researchers can access the data to ensure privacy and confidentiality. Data 
will be presented as grouped data and will not identify individual subject. 
 
4.2. Baseline Data 
Table 1: Baseline Demographic and Clinical Characteristic for Each Group 
Characteristic  Interventio




Age (years)    
  
Male     
Female     
  
Malay    
Chinese    
Others    
Height (cm) 
Underweight     
Normal     
Obese     
Weight (kg) 
BMI (kg/m²)    
BP    
Tanner Staging  
Pre-pubertal    
Post-pubertal     
Duration of DM 
(months) 
   
Insulin Treatment:  
    No of 
Injection/day 
   
Types of insulin   
           Analog    
